Eli Lilly piles on weight loss drug suits to ward off revenue squeeze

Lawsuits against pharmacies in seven states aim to protect its flagship Mounjaro and Zepbound medications | Growing competition and patent expiration increase urgency for Lilly | New Jersey and Delaware stores accused of selling unapproved tirzepatide-based products.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Americas

Court upholds $83m sequencing verdict and sets royalty rate

17 June 2026 A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.

Americas

Amgen and subsidiary dealt $20m blow over rodent antibody tech

15 June 2026 Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.

Americas

Moderna: BioNTech is claiming work ‘it never did’

12 June 2026 In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.

More features

Novartis pursues Apotex over copies of $2bn skin cancer drug franchise

MSD’s Keytruda hit by eight-country ban across Europe

Foley Hoag adds two partners in Denver expansion

WATCH: LEO Pharma head of IP rights on doing more with less

Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom

Latham adds ‘exceptional’ ITC expert and 5th trial lawyer in a year

Roche, Marques counsel: The fight against ‘deadly’ counterfeits is a race for the newest and best tech

Fish & Richardson nets patent litigator to grow European practice

Eli Lilly piles on weight loss drug suits to ward off revenue squeeze

More on this story

Editor's picks

Editor's picks

More features